Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Jul;67(1):92-9.
doi: 10.1086/302960. Epub 2000 May 24.

Genomewide Scan for Prostate Cancer-Aggressiveness Loci

Affiliations
Free PMC article

Genomewide Scan for Prostate Cancer-Aggressiveness Loci

J S Witte et al. Am J Hum Genet. .
Free PMC article

Abstract

The aggressiveness of prostate cancer (PCa) varies widely: some tumors progress to invasive, potentially life-threatening disease, whereas others stay latent for the remainder of an individual's lifetime. The mechanisms resulting in this variability are not yet understood, but they are likely to involve both genetic and environmental influences. To investigate genetic factors, we conducted a genomewide linkage analysis of 513 brothers with PCa, using the Gleason score, which reflects tumor histology, as a quantitative measure of PCa aggressiveness. To our knowledge, this is the first time that a measure of PCa aggressiveness has been directly investigated as a quantitative trait in a genomewide scan. We employed a generalized multipoint Haseman-Elston linkage-analysis approach that regresses the mean-corrected cross product between the brothers' Gleason scores on the estimated proportion of alleles shared by brothers identical by descent at each marker location. Our results suggest that candidate regions on chromosomes 5q, 7q, and 19q give evidence for linkage to PCa-aggressiveness genes. In particular, the strongest signals detected in these regions were at the following markers (with corresponding P values): for chromosome 5q31-33, between markers D5S1480 and D5S820 (P=.0002); for chromosome 7q32, between markers D7S3061 and D7S1804 (P=.0007); and, for chromosome 19q12, at D19S433 (P=.0004). This indicates that one or more of these candidate regions may contain genes that influence the progression of PCa from latent to invasive disease. Identification of such genes would be extremely valuable for elucidation of the mechanism underlying PCa progression and for determination of treatment in men in whom this disease has been diagnosed.

Figures

Figure  1
Figure 1
Results from a genomewide scan of PCa-aggressiveness genes; Gleason score was used as a quantitative trait. Unbroken lines denote results from the new HE analysis; broken lines denote results from the original HE analysis. Tick marks across horizontal axes indicate marker locations (in cM) (as specified on the Center for Human Genetics, Marshfield Medical Research Foundation Web site). P values are from a t test of the HE regression coefficient, with 324 df (number of affected sib pairs [326] minus the number of parameters [2]). Dotted horizontal lines indicate where P=.001 (−log[P] = 3); thus, for peaks above these lines, P<.001.

Similar articles

See all similar articles

Cited by 46 articles

  • Downregulation of CPA4 inhibits non small-cell lung cancer growth by suppressing the AKT/c-MYC pathway.
    Fu Y, Su L, Cai M, Yao B, Xiao S, He Q, Xu L, Yang L, Zhao C, Wan T, Shao L, Wang L, Huang X. Fu Y, et al. Mol Carcinog. 2019 Nov;58(11):2026-2039. doi: 10.1002/mc.23095. Epub 2019 Aug 9. Mol Carcinog. 2019. PMID: 31397502 Free PMC article.
  • Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer.
    Xia Y, Huang CC, Dittmar R, Du M, Wang Y, Liu H, Shenoy N, Wang L, Kohli M. Xia Y, et al. Oncotarget. 2016 Jun 14;7(24):35818-35831. doi: 10.18632/oncotarget.9027. Oncotarget. 2016. PMID: 27127882 Free PMC article.
  • Two susceptibility loci identified for prostate cancer aggressiveness.
    Berndt SI, Wang Z, Yeager M, Alavanja MC, Albanes D, Amundadottir L, Andriole G, Beane Freeman L, Campa D, Cancel-Tassin G, Canzian F, Cornu JN, Cussenot O, Diver WR, Gapstur SM, Grönberg H, Haiman CA, Henderson B, Hutchinson A, Hunter DJ, Key TJ, Kolb S, Koutros S, Kraft P, Le Marchand L, Lindström S, Machiela MJ, Ostrander EA, Riboli E, Schumacher F, Siddiq A, Stanford JL, Stevens VL, Travis RC, Tsilidis KK, Virtamo J, Weinstein S, Wilkund F, Xu J, Lilly Zheng S, Yu K, Wheeler W, Zhang H; African Ancestry Prostate Cancer GWAS Consortium, Sampson J, Black A, Jacobs K, Hoover RN, Tucker M, Chanock SJ. Berndt SI, et al. Nat Commun. 2015 May 5;6:6889. doi: 10.1038/ncomms7889. Nat Commun. 2015. PMID: 25939597 Free PMC article.
  • Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases.
    Helfand BT, Roehl KA, Cooper PR, McGuire BB, Fitzgerald LM, Cancel-Tassin G, Cornu JN, Bauer S, Van Blarigan EL, Chen X, Duggan D, Ostrander EA, Gwo-Shu M, Zhang ZF, Chang SC, Jeong S, Fontham ET, Smith G, Mohler JL, Berndt SI, McDonnell SK, Kittles R, Rybicki BA, Freedman M, Kantoff PW, Pomerantz M, Breyer JP, Smith JR, Rebbeck TR, Mercola D, Isaacs WB, Wiklund F, Cussenot O, Thibodeau SN, Schaid DJ, Cannon-Albright L, Cooney KA, Chanock SJ, Stanford JL, Chan JM, Witte J, Xu J, Bensen JT, Taylor JA, Catalona WJ. Helfand BT, et al. Hum Genet. 2015 Apr;134(4):439-50. doi: 10.1007/s00439-015-1534-9. Epub 2015 Feb 26. Hum Genet. 2015. PMID: 25715684 Free PMC article.
  • A systems genetics approach identifies CXCL14, ITGAX, and LPCAT2 as novel aggressive prostate cancer susceptibility genes.
    Williams KA, Lee M, Hu Y, Andreas J, Patel SJ, Zhang S, Chines P, Elkahloun A, Chandrasekharappa S, Gutkind JS, Molinolo AA, Crawford NP. Williams KA, et al. PLoS Genet. 2014 Nov 20;10(11):e1004809. doi: 10.1371/journal.pgen.1004809. eCollection 2014 Nov. PLoS Genet. 2014. PMID: 25411967 Free PMC article.
See all "Cited by" articles

Publication types

Substances

Feedback